EHA 2023 | Phase I study of CD22 CAR-T therapy in patients with LBCL who have relapsed after CD19 CAR-T therapy
Matthew Frank, MD, PhD, Stanford University, Stanford, CA, shares the results of a Phase I study (NCT04088890) evaluating an autologous CAR-T therapy targeting CD22 for the treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have predominantly relapsed after treatment with a CD19 CAR-T therapy. The study reported durable complete responses (CR) and high overall response rates (ORR) at the recommended Phase II dose. In terms of toxicity, patients did experience cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH)-like toxicity, and low grade-neurotoxicity, but these adverse events were all manageable. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
